Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. Our aim was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a 24-week treatment period (the phase 3 AP...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2021-07, Vol.148 (1), p.164-172.e9
Hauptverfasser:	Zuraw, Bruce, Lumry, William R., Johnston, Douglas T., Aygören-Pürsün, Emel, Banerji, Aleena, Bernstein, Jonathan A., Christiansen, Sandra C., Jacobs, Joshua S., Sitz, Karl V., Gower, Richard G., Gagnon, Remi, Wedner, H. James, Kinaciyan, Tamar, Hakl, Roman, Hanzlíková, Jana, Anderson, John T., McNeil, Donald L., Fritz, Stephen B., Yang, William H., Tachdjian, Raffi, Busse, Paula J., Craig, Timothy J., Li, H. Henry, Farkas, Henriette, Best, Jessica M., Clemons, Desiree, Cornpropst, Melanie, Dobo, Sylvia M., Iocca, Heather A., Kargl, Deborah, Nagy, Eniko, Murray, Sharon C., Collis, Phil, Sheridan, William P., Maurer, Marcus, Riedl, Marc A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Angioedema BCX7353 berotralstat C1 inhibitor Complement component C1 Diarrhea Disease prevention Dosage Double-blind studies Drug dosages Edema efficacy HAE hereditary angioedema Kallikrein kallikrein inhibitor Laboratories long-term prophylaxis Pain Placebos Plasma kallikrein Prophylaxis Quality of life Questionnaires safety Software Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!